John Murray

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

Patrick Hayden, Claire Roddie, Peter Bader et al. · Annals of Oncology · 2021 · 389 citations · Full text

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Ibrahim Yakoub‐Agha, Christian Chabannon, Peter Bader et al. · Haematologica · 2019 · 343 citations · Full text

Cell Therapy, Immunology, Transplantation Medicine +24

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial

John G.F. Cleland, John R. Teerlink, Roxy Senior et al. · The Lancet · 2011 · 329 citations

Cardiomyopathy, Heart Failure, Omecamtiv Mecarbil +10

Trends in resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States: 2013–2017

Vikas Gupta, Gang Ye, Melanie Olesky et al. · BMC Infectious Diseases · 2019 · 64 citations · Full text

Systemic Lupus Erythematosus, Cirrhosis and Ulcerative Colitis after Thymectomy for Myasthenia Gravis

Richard F. Galbraith, W.H.J. Summerskill, John Murray · New England Journal of Medicine · 1964 · 54 citations

Immunology, Dermatology, Immunotherapy +17